Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

Objective: To evaluate the efficacy and tolerability of anti-tumour necrosis factor α (TNFα) monoclonal antibody (infliximab) in the treatment of spondyloarthropathy (SpA) associated with active and inactive Crohn’s disease (CD). Methods: Twenty four patients with SpA associated with active or inact...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2004-12, Vol.63 (12), p.1664-1669
Main Authors: Generini, S, Giacomelli, R, Fedi, R, Fulminis, A, Pignone, A, Frieri, G, Del Rosso, A, Viscido, A, Galletti, B, Fazzi, M, Tonelli, F, Matucci-Cerinic, M
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis
BASDAI
Bath Ankylosing Spondylitis Disease Activity Index
Biological and medical sciences
C reactive protein
C-Reactive Protein - metabolism
CDAI
Crohn Disease - blood
Crohn Disease - complications
Crohn Disease - drug therapy
Crohns disease
Crohn’s disease
Crohn’s Disease Activity Index
CRP
Cytokines
Drugs
erythrocyte sedimentation rate
ESR
Extended Report
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
IBD
Immunomodulators
Inflammation
Inflammatory bowel disease
Infliximab
Laboratories
Male
Medical sciences
Middle Aged
non-steroidal anti-inflammatory drugs
NSAIDs
Other diseases. Semiology
Pain Measurement
Patients
Pharmacology. Drug treatments
Quality of life
Remission Induction
Resorts & spas
rheumatoid arthritis
Severity of Illness Index
SpA
Spondylarthropathies - blood
Spondylarthropathies - drug therapy
Spondylarthropathies - etiology
spondyloarthropathies
spondyloarthropathy
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
TNFα
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
tumour necrosis factor α
ultrasonography
VAS
visual analogue scale
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To evaluate the efficacy and tolerability of anti-tumour necrosis factor α (TNFα) monoclonal antibody (infliximab) in the treatment of spondyloarthropathy (SpA) associated with active and inactive Crohn’s disease (CD). Methods: Twenty four patients with SpA associated with active or inactive CD (16 active, 8 quiescent) were treated with anti-TNFα monoclonal antibody (infliximab) with repeated infusions for a period of 12–18 months. The treatment aimed at ameliorating the general musculoskeletal and spinal pain, controlling peripheral arthritis and enthesitis, decreasing the BASDAI score, modifying acute phase reactants, and reducing CD activity. Results: Infliximab improved both gastrointestinal (p
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.2003.012450